Generics/Research

History and future of pay-for-delay

Generics/Research | Posted 23/11/2012

Pay-for-delay is a constant issue in both the US and Europe. But how did these settlements first come about and how have US courts attitudes towards such deals affected the pharmaceutical market [1].

Overview of clinical research on generics in 2012

Generics/Research | Posted 09/11/2012

Period: January to August 2012

Generic drug alternatives to brand-name prescription medications are becoming increasingly important in the global drug market as governments strive to contain healthcare costs and as an increasing number of prescription drugs lose patent protection.

Suggestions for increasing generics use in Abu Dhabi

Generics/Research | Posted 05/10/2012

This concluding article in a series of three suggests ways of improving the use of generics in Abu Dhabi.

Use of generics in Abu Dhabi

Generics/Research | Posted 21/09/2012

The second of three articles examining how to increase generics use in Abu Dhabi.

Maximising the potential of generics in Abu Dhabi

Generics/Research | Posted 14/09/2012

Introduction
All residents in Abu Dhabi have access to health care via mandatory health insurance. Nationals, who comprise 20% of the population with two-thirds under 30 years of age and half under 19 years of age, have automatic access to comprehensive health care funded by the government. In 2008, all nationals received cards giving free access to health care and choice of provider in both the public and private sectors [1].

Misunderstandings regarding generics in Pakistan

Generics/Research | Posted 07/09/2012

This article is the third of three articles covering the results of a survey investigating the knowledge, perception and attitude of general practitioners (GPs) towards generic medicines in Karachi, Pakistan [1].

Facts about generics for patients

Generics/Research | Posted 24/08/2012

The costs of health care are rising across Europe through ageing populations resulting in more patients with chronic diseases, stricter clinical targets for managing patients with long term (chronic) diseases, the continued launch of new and more expensive drugs as well as rising patient expectations.

Attitude of general practitioners towards generics in Pakistan

Generics/Research | Posted 24/08/2012

The second of a series of three articles reports on a survey aimed at exploring the knowledge, perception and attitude of general practitioners towards generic medicines in Karachi, Pakistan [1].

Generics in Pakistan

Generics/Research | Posted 17/08/2012

This is the first of a series of three articles on the problems facing Pakistan in making health care affordable to ordinary people.

Management of drugs shortages

Generics/Research | Posted 22/06/2012

The number, range and duration of drug shortages in the US appear to be, at best, maintaining the levels seen in the recent past. It is now becoming essential for institutions to draft formal policies and procedures to manage them. An article by two hospital pharmacists summarises the information available and outlines the steps needed to make the best of the situation [1].

Attitudes and beliefs are powerful influences on generics use

Generics/Research | Posted 08/06/2012

While generic drugs have the potential to provide significant savings in healthcare costs, and numerous financial incentives are in place, the generics substitution rate in Switzerland was, until recently, lower than expected. A report by Decollogny et al. shows that attitudes and beliefs among patients and physicians have a powerful influence on prescribing practice, suggesting that educational campaigns could potentially provide a significant boost to generics use [1].

Efficacy and tolerability of generic and brand-name atorvastatin

Generics/Research | Posted 01/06/2012

A generic formulation of atorvastatin was developed in Korea and approved by Korea Food and Drug Administration on 1 July 2008. This clinical trial was conducted at ten clinical centres in Korea between September 2008 and May 2010 for the purposes of marketing the generic formulation [1].

Increased use of generic statins proves cost effective in Australia

Generics/Research | Posted 25/05/2012

A recent study concluded that closing the statin ‘treatment gap’ using generics was cost-effective in the secondary prevention of coronary artery disease (CAD) in Australia [1].

Can generic competition succeed at reducing cost of atorvastatin?

Generics/Research | Posted 11/05/2012

The generic form of the cholesterol-lowering drug Lipitor (atorvastatin) has the potential for significant cost savings for payers following its introduction in November 2011. However, ‘aggressive business tactics’ by Pfizer may stifle generics competition and so prevent prices from falling as much as predicted.

Comparison of brand-name and biosimilar etanercept in Korea

Generics/Research | Posted 04/05/2012

A study comparing pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg) in Korea reported by Gu et al has shown that the reference drug and the test biosimilar met the standard criteria for assuming bioequivalence as defined by Korean regulatory authorities [1].

Cheap generic drug stops fatal bleeding but gets little use

Generics/Research | Posted 13/04/2012

According to a systematic review of data, use of a cheap generic drug could potentially save many trauma patients every year [1].

Patients do not talk about generics with doctors

Generics/Research | Posted 06/04/2012

One of the main financial concerns expressed by adults in the US is the cost of medications and medical bills, however, despite this fact, very few patients talk about the price of prescription medicines with their physicians, according to Consumer Reports' monthly nationally representative survey [1].

Attitudes towards prescribing generics in Malaysia

Generics/Research | Posted 30/03/2012

A recent study carried out in Malaysia has shown that pharmacists in the country have a lack of confidence in generic medicines produced by local pharmaceutical companies [1].

Brand-name atorvastatin cheaper than generics

Generics/Research | Posted 23/03/2012

Despite generics of Pfizer’s blockbuster cholesterol-reducing drug Lipitor (atorvastatin) being available in the US since the patent expired in November 2011, many patients are still receiving the brand-name drug [1].

Cost savings due to prescribing of generic PPIs and statins in Scotland

Generics/Research | Posted 16/03/2012

Significant cost savings can be made by governments by encouraging prescribing of generics rather than brand-name drugs. In Scotland, in an effort to control medicines expenditure, measures were introduced in 2000 to encourage the prescribing of generic proton pump inhibitors (PPIs) and statins [1].

Generics and biosimilars Initiative

News

Research

General